Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
US11162103B2 · kind B2 · utility
0Cited by
4References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2021 |
| Grant date | Nov 2, 2021 |
| Priority date | — |
| Expiry date | Feb 22, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/351
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the apolipoprotein C3 gene (APOC3). The invention also relates to methods of using such RNAi agents to inhibit expression of an APOC3 gene and to methods of preventing and treating an APOC3-associated disorder, e.g., hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, polycystic ovary syndrome, kidney disease, obesity, type 2 diabetes mellitus (insulin resistance), hypertension, artherosclerosis and pancreatitis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.